Anebulo Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Richie Cunningham

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführerless than a year
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.3yrs

Jüngste Management Updates

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Geschäftsführer

Richie Cunningham (53 yo)

less than a year

Amtszeit

Mr. Richard Anthony Cunningham, also known as Richie, is Chief Executive Officer and Director of Anebulo Pharmaceuticals, Inc. since October 2023. He served as Chief Executive Officer and Director at Tyme...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Joseph Lawler
Founder & Chairman4.2yrsUS$11.00k46.27%
$ 31.6m
Kenneth Cundy
Chief Scientific Officer2.1yrsUS$495.63k0%
$ 0
Richard Cunningham
CEO & Directorless than a yearkeine Datenkeine Daten
Daniel George
Principal Accounting Officerless than a yearkeine Datenkeine Daten
Scott Anderson
Head of Investor Relations & Public Affairs2.4yrskeine Datenkeine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

53.5yo

Durchschnittliches Alter

Erfahrenes Management: ANEBDas Führungsteam des Unternehmens gilt als erfahren (2.1 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Joseph Lawler
Founder & Chairman4.2yrsUS$11.00k46.27%
$ 31.6m
Richard Cunningham
CEO & Directorless than a yearkeine Datenkeine Daten
Bimal Shah
Independent Directorless than a yearkeine Datenkeine Daten
Kenneth Lin
Lead Independent Director3.3yrsUS$1.00k0%
$ 0
Areta Kupchyk
Independent Director3.2yrsUS$11.00k0%
$ 0
Jason Aryeh
Independent Director3.3yrsUS$21.00k0%
$ 0
Nathaniel Calloway
Independent Director1.7yrsUS$79.75kkeine Daten
Aron English
Independent Director4yrsUS$1.00k17.95%
$ 12.2m
Andrew Monte
Member of Scientific Advisory Board3.4yrskeine Datenkeine Daten
Arjun Chanmugam
Member of Scientific Advisory Board3.4yrskeine Datenkeine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrener Vorstand: ANEBDie Vorstandsmitglieder gelten als erfahren (3.3 Jahre durchschnittliche Amtszeit).